Notwithstanding the improvement in treatment results for paediatric T cell acute lymphoblastic leukaemia (T-ALL) it remains important to understand if genetic aberrations influence therapy response. PTEN tumour suppressor gene inactivation is a frequent event in T-ALL but its effect on patient therapy response is debatable. We analysed the effect of the presence of mutated PTEN on outcome in 257 children with T-ALL treated with Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)-BerlinFrankf€ urt-M€ unster (BFM) protocols. PTEN mutations were present in 31 (12Á1%) patients and were significantly associated with increased risk of relapse. PTEN mutations also indicate a poor prognosis in T-ALL patients in the absence of NOTCH1 mutations or in the group of patients with copresence of PTEN mutation and deletions. These results indicate that PTEN genomic aberrations and the biologically consequential PTEN inactivation contribute to adverse therapy response in T-ALL patients; PTEN status as a biomarker may contribute to the development of new molecularly-defined stratification algorithms.
Summary
Notwithstanding the improvement in treatment results for paediatric T cell acute lymphoblastic leukaemia (T-ALL) it remains important to understand if genetic aberrations influence therapy response. PTEN tumour suppressor gene inactivation is a frequent event in T-ALL but its effect on patient therapy response is debatable. We analysed the effect of the presence of mutated PTEN on outcome in 257 children with T-ALL treated with Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)-BerlinFrankf€ urt-M€ unster (BFM) protocols. PTEN mutations were present in 31 (12Á1%) patients and were significantly associated with increased risk of relapse. PTEN mutations also indicate a poor prognosis in T-ALL patients in the absence of NOTCH1 mutations or in the group of patients with copresence of PTEN mutation and deletions. These results indicate that PTEN genomic aberrations and the biologically consequential PTEN inactivation contribute to adverse therapy response in T-ALL patients; PTEN status as a biomarker may contribute to the development of new molecularly-defined stratification algorithms.
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T cell acute lymphoblastic leukaemia (T-ALL) represents 10-15% of newly diagnosed paediatric cases of ALL (Paganin & Ferrando, 2011) . Historically, the T immunophenotype was considered to be an unfavourable prognostic feature but the use of intensive chemotherapy and treatment modulation based on patient response, measured as minimal residual disease (MRD), has resulted in an improved overall survival at 7 years from diagnosis of approximately 80% in BerlinFrankf€ urt-M€ unster (BFM)-based treatment protocols (Schrappe et al, 2011; Conter et al, 2016) .
Despite efforts to identify genetic alterations and biological features that could be used in the context of treatment stratification, the role of genetics in childhood T-ALL remains controversial.
The identification of recurrent mutations in NOTCH1, a key regulator of T cell fate specification and a thymocyte development factor, in 50-60% of T-ALL and the possibility to inhibit the activation of NOTCH receptors provided the opportunity to develop molecular therapies targeting the NOTCH1 signalling pathway (Palomero et al, 2008; Belver research paper & Ferrando, 2016) . However, the picture of genomic aberrations in T-ALL transpired to be more complex. One group demonstrated that NOTCH1 controls a transcriptional network (HES1 and MYC) that regulates the expression of the tumour suppressor, phosphatase and tensin homolog (PTEN), a negative regulator of phosphatidyl-inositol 3-kinase (PI3K)-AKT signalling, in normal thymocytes and in leukaemic T cell. PTEN mutations were discovered in T-ALL cell lines resistant to NOTCH1-inhibitors (csecretase); this study suggested that a mutational loss of PTEN induces an oncogene addiction switch that renders T-ALL cells dependent to constitutively active AKT signalling, bypassing the requirement for aberrant NOTCH1 signalling in leukaemic cell growth (Palomero et al, 2007 (Palomero et al, , 2008 Belver & Ferrando, 2016) . PTEN is found to be inactivated in a variety of cancer types (Mendes et al, 2016) . Recurrently, T-ALL showed loss of the PTEN tumour suppressor gene as a result of loss-of-function mutations or deletions, with a frequency rate around 15% (Belver & Ferrando, 2016) .
Within this scenario, PTEN status could be a candidate biomarker for refining early patient stratification at diagnosis. In line with this, several leukaemia study groups have analysed the association of PTEN abnormalities with relapse and/ or survival rates, alone or in association with NOTCH1 mutation status (Gutierrez et al, 2009; Larson Gedman et al, 2009; Jotta et al, 2010; Zuurbier et al, 2012; Bandapalli et al, 2013; Trinquand et al, 2013; Mendes et al, 2014; Jenkinson et al, 2016; Tesio et al, 2017) . Up to now, in spite of the above studies, the prognostic value of genomic PTEN aberrations in T-ALL remains an open issue. Bandapalli et al (2013) reported PTEN mutations were associated with a trend towards poor long-term outcome in T-ALL patients, an effect that was neutralized by the co-presence of NOTCH1 mutations in patients treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)-BFM ALL 2000 Protocol in BFM Centres (Bandapalli et al, 2013) . Considering these data, here we analysed PTEN by sequencing the predominantly mutated exon 7, in a cohort of AIEOP T-ALL paediatric patients and evaluated the impact on clinical outcome of PTEN mutation status in combination with the mutation status of NOTCH1. In addition, we analysed PTEN mutations jointly with PTEN deletion status, because a previous study of paediatric T-ALL patients reported small deletions for PTEN possibly inactivating PTEN (Mendes et al, 2014) .
Methods and samples
We analysed a cohort of 271 T-ALL patients treated in AIEOP centres according to AIEOP-BFM ALL 2000 or AIEOP ALL R2006 protocols (NCT00613457; n = 184) and the subsequent AIEOP-BFM ALL 2009 protocol (EudraCT number 2007-004270-43; n = 87) representing 39% of the total cohort of 697 T-ALL patients enrolled in Italian centres between September 2000 and December 2015. These study protocols were approved by the Ethics committees, and informed consent was obtained for all patients. Treatment details of the AIEOP-BFM ALL 2000 protocol were published earlier (Schrappe et al, 2011; Lo Nigro et al, 2013; Conter et al, 2016) . The AIEOP-BFM ALL 2009 study differs from the previous AIEOP-BFM ALL 2000 protocol in four major points: (i) high MRD at day +15 [≥10% of blasts in bone marrow (BM) detected by flow cytometry (FCM)] is added as a high risk (HR) criterion; (ii) patients who are prednisone poor responder (PPR) receive an additional dose of cyclophosphamide (1 g/m 2 ) at day 10 of phase IA; (iii) Pegylated L-Asparaginase is substituted for native E-Coli L-Asparaginase; (iv) non HR patients receive protocol II (Conter et al, 2016) . Acute leukaemia was diagnosed when 25% of blasts were recorded in the bone marrow at morphological evaluation. The T cell origin of ALL was defined by a blast cell surface or cytoplasmic CD3 immunophenotype (Basso et al, 2001; Vardiman et al, 2009; Dworzak et al, 2017) . T-ALL was routinely sub-classified according to the European Group for the Immunologic Characterization of Leukaemias definition: early T cell precursor, early, cortical (or intermediate), and mature (Conter et al, 2016; Dworzak et al, 2017) . MRD was classified as high-risk MRD (HR-MRD) if MRD was ≥5 9 10 À4 at day 78, and non-HR for the remaining patients. The study patients here reported were selected on the basis of sample availability and are comparable to the total cohort of patients in terms of characteristics and eventfree survival (EFS) (Table SI and Figure S1 ). Sequencing analysis of PTEN exon 7 and NOTCH1 exons 26, 27, 28 and 34 (TAD and PEST domain) was performed on primary genomic DNA or after whole genome amplification and the identification of mutations was manually checked after blast analysis. PTEN deletions were detected by Multiplex ligation-dependent probe amplification with a commercial kit (MRC-Holland, Amsterdam, Netherlands) and customized probes.
Statistical analysis
Event-free survival (EFS) was calculated from date of diagnosis to date of event. Events considered were resistance, relapse, death or second neoplasm, whichever occurred first. Time was censored at last follow-up if no event was reported. EFS curves were estimated according to Kaplan-Meier with standard error (SE) calculated according to Greenwood formula, differences between groups were compared with the log-rank test. Cumulative incidence functions for competing events were constructed by the method of Kalbfleisch and Prentice and were compared with the Gray test.
Follow-up was updated at January 2014 for AIEOP-BFM ALL 2000/R2006 and at January 2017 for AIEOP-BFM ALL 2009. Analyses were done with SAS software version 9.4 (SAS Institute, Cary, NC, USA).
Results
PTEN mutations were detected in 31 (12Á1%) of the 257 patients tested. As shown in Table IA , 12 of the mutated patients relapsed, all within 2 years from diagnosis, resulting in a 5-year cumulative incidence of relapse (CIR) of 38Á7% (SE 8Á7) which was significantly different from that observed in unmutated patients, i.e. 5-year CIR of 20Á2% (SE 2Á8) (P = 0Á004, Fig 1) . The worst outcome of mutated patients is seen also in the estimated EFS, with a 5-year figure of 58Á1% (SE 8Á9) compared to 73Á1% (SE 3Á1) in unmutated patients (P = 0Á02, Figure S2A ).
The presence of mutated NOTCH1 was detected in 165 of the 251 patients (65Á7%) assessed. Of the mutated patients, 31 relapsed resulting in a 5-year CIR of 21Á6% (SE 3Á6) vs. 26Á2% (SE 4Á8) in unmutated patients (P = 0Á17, Figure S3 ). The worst outcome of unmutated patients is seen in the estimated EFS, with a 5-year figure of 63Á3% (SE 5Á3) compared to 74Á1% (SE 3Á8) in mutated, due also to a higher rate of other type of events in the earlier group (6 deaths, 3 second malignant neoplasms and 1 resistant patient; P = 0Á01, Figure S2B) .
When we analysed the joint influence of the presence of PTEN and NOTCH1 mutations in the cohort of 237 patients evaluated for both aberrations, we found that the worst outcome was seen in the group of patients with mutated PTEN and absence of NOTCH1 mutations compared with the remaining patients, with a 5-year CIR of 40Á9% (SE 10Á5) for the PTEN mutated and NOTCH1 unmutated vs. 21Á2% (SE 3Á0) in the other patients (P = 0Á008, Fig 2 and Table IA) . Of note, only 6 out of 237 patients (2Á5%) had both PTEN and NOTCH1 mutations and 2 of them experienced a relapse. The other two subgroups (PTEN unmutated and Table I . Distribution of events in evaluated patients according to PTEN mutation and deletion and NOTCH1 mutation.
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Mutated and deleted Other Figure S4 ). The worst outcome of PTEN mutated and NOTCH1 unmutated patients is seen also in the EFS, with a 5-year figure of 59Á1% (SE 10Á5), compared to 72Á2% (SE 3Á2) for the remaining patients (P = 0Á07, Figure S2C ). Presence of simultaneous PTEN deletions and mutations was evaluated in 213 patients. We detected aberrant PTEN in 37 out of 213 (17Á4%) patients; 14 out of 213 (6Á6%) presented both mutation and deletion (Table IA) . Patients with co-presence of the two aberrations had a 5-year CIR of 42Á9% (SE 13Á2), which was significantly different from the CIR of 20Á2% (SE 3Á1) for the other patients (P = 0Á01, Fig 3A) . This latter group included patients who presented in PTEN only a mutation (CIR 27Á3%) (SE 13Á4), or only a deletion (CIR 8Á3%) (SE 8Á0) or without any aberrations (CIR 20Á7%) (SE 3Á4) (Fig 3B) .
The prognostic role of PTEN and NOTCH1 alterations was assessed within subgroups of MRD-HR versus MRD non-HR patients as defined by MRD level at the end of consolidation therapy. As shown in Table IB the large non-HR group shows similar trends as observed for all patients regardless of MRD risk group. The presence of mutated PTEN remained significantly different from unmutated patients, although this was borderline with a CIR of 30Á4% (SE 9Á6) and 17Á1% (SE 3) respectively (P = 0Á05, Figure S5 ). The number of patients in the MRD HR group was too small to allow meaningful conclusions to be drawn (Table IC) . A Cox regression model was applied to evaluate the role of the simultaneous deletion and mutation of PTEN after adjusting for major known prognostic factors, i.e. MRD, white blood cell count and response to prednisone. While results confirm the independent significance of MRD (hazard ratio = 2Á08, P = 0Á02) and response to prednisone (hazard ratio = 2Á55, P = 0Á001), the alteration of PTEN was related to a 20% increase in the hazard ratio, but this did not reach significance (hazard ratio = 1Á20, P = 0Á69).
Discussion
Several T-ALL paediatric patient cohorts have been analysed for PTEN mutations and aberrations with the aim to understand if the PTEN mutational status can be used for treatment stratification. However thus far, the prognostic significance of PTEN mutations at diagnosis of T-ALL remained elusive.
Here we present data on the analysis of PTEN mutations in the AIEOP cohort, finding that patients harbouring the Fig 2. Analyses of Cumulative Incidence of Relapse (CIR) of patients with mutated PTEN and unmutated NOTCH1 compared with the other patients (mutated in PTEN and NOTCH1, mutated in NOTCH1 only or unmutated); patients mutated in PTEN but without a NOTCH1 mutation had a higher 5-year CIR (P = 0Á008). Cum, Cumulative; pts, patients; rel., relapse. [Colour figure can be viewed at wileyonlinelibrary.com Patients divided based on PTEN mutation and deletion status compared with the co-presence of the two aberrations, with mutations only, with deletions only or without these aberrations. Cum, Cumulative; MUT&DEL, mutated and deleted; pts, patients; rel., relapse; WT, wild-type. [Colour figure can be viewed at wileyonline library.com exon 7 mutation have a higher incidence of relapse compared with patients not presenting this mutation, with relapses occurring within the 2 years of therapy. When we consider also the mutation status of NOTCH1 and the presence of PTEN deletions, the presence of mutations in PTEN remain a useful genetic characteristic that predicts a worse outcome also in the absence of NOTCH1 mutations or in the presence of PTEN deletions. In 2010 it was reported that PTEN mutations, detected by sequencing exon 1 and 7, were significantly associated with lower OS and EFS in paediatric T-ALL patients treated in the high-risk group of the Brazilian GBTL1 protocol (Jotta et al, 2010) . Later, Bandapalli et al (2013) reported that the presence of mutated PTEN was associated with a tendency towards a poorer long-term outcome and a poor early treatment response in patients receiving BFM therapy. In addition, the PTEN mutated and NOTCH1 unmutated group had a significantly lower EFS (Bandapalli et al, 2013) . Our data support this trend toward a worse response to BFM therapy in PTEN-mutated patients.
The negative impact of PTEN abnormalities on outcome in T-ALL paediatric patients treated on the Medical Research Council UKALL2003 trial was not confirmed: PTEN loss-offunction mutations/gene deletions did not affect response to therapy or long-term outcome (Jenkinson et al, 2016) . The mutation status of PTEN was also not associated with treatment outcome in the report from the Children's Oncology Group; however, in the latter study, the number of PTEN mutated cases may have been overestimated due to the presence of the PTEN pseudogene (Jotta et al, 2010) .
Another study, which used array comparative genomic hybridization (aCGH), fluorescence in situ hybridization (FISH) and sequence analysis to investigate the frequency and prognostic implication of PTEN, PIK3CA (also termed PI3K) and AKT1 (also termed AKT) abnormalities in childhood T-ALL, showed that the presence of genetic alterations in the PTEN-PI3K-AKT pathway did not predict EFS, whereas the presence of PTEN deletions was reported to be significantly associated with early treatment failure (Gutierrez et al, 2009) . PTEN aberrations and outcome has been investigated also in the Dutch Childhood Oncology Group and the German Cooperative study group for childhood ALL protocols, showing that the presence of NOTCH1 mutations and PTEN/AKT1 mutations did not significantly predict for increased risk of relapse in univariate analyses, but these mutations were independent risk factors along with male gender in multivariate analysis; T-ALL patients lacking PTEN/AKT1 mutations and carrying NOTCH1-activating mutations had a good outcome (Zuurbier et al, 2012) .
PTEN mutations are not the only aberration that contributes to the loss of PTEN protein in T-ALL patient samples. A previous study showed that 8% of paediatric T-ALL patients had small deletions affecting a few exons of PTEN, possibly inactivating PTEN or resulting in absence of the protein (Mendes et al, 2014) . In the French group for childhood ALL (FRALLE) trail, the presence of PTEN abnormalities have been associated with reduced disease-free survival but not lower overall survival in the paediatric cohort; the study underlines that the genomic mechanism of PTEN alteration determined the prognostic impact (Tesio et al, 2017) . Therefore, we analysed T-ALL patient outcome, adding information on PTEN deletion status to that of PTEN mutations.
In the above discussed reports, patient samples were analysed with different methods and/or treatment protocols were not the same. Moreover, comparing data of genomic studies of T-ALL cohorts (for the clinical impact of PTEN) is hampered as the compared groups of patients may carry specific combinations of mutations or genomic aberrations, not only of PTEN. Nevertheless, even if this can be one of the reasons why results vary between different studies, it also indicates that the presence of PTEN aberrations is not a particularly strong genetic prognostic marker and validation in the context of different conditions was strongly advised (Gutierrez et al, 2009; Larson Gedman et al, 2009; Jotta et al, 2010; Zuurbier et al, 2012; Bandapalli et al, 2013; Trinquand et al, 2013; Mendes et al, 2014; Jenkinson et al, 2016; Tesio et al, 2017) .
This AIEOP study on 271 T-ALL patients suggests that PTEN mutation sequencing analysis, by itself but also in combination with NOTCH1 analysis and PTEN deletion analysis, can identify a group of patients with a higher probability of relapsing, providing relevance to PTEN aberrations as a prognostic marker; notwithstanding that the prognostic value of MRD and response to prednisone remain consolidated independent prognostic factors. In the future, it would be really insightful to perform a meta-analysis of patients from several T-ALL cohorts for which data of PTEN aberration analyses are available so that a conclusion can be achieved on the clinical utility of including PTEN analyses in the diagnostic work-up for risk classification and improvement in the therapeutic protocols for paediatric T-ALL patients.
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Fig S1. Event Free Survival (EFS) of analyzed vs not analyzed AIEOP T-ALL patients. The two cohorts show a comparable 5-year EFS (P = 0.91).
Fig S2. Event Free Survival (EFS) analyzed of: (A) mutated PTEN patients compared to patients without mutated PTEN: patients with PTEN mutations had an lower 5-year EFS (P = 0.02); (B) patients with mutated NOTCH1 compared to patients without mutated NOTCH1: patients with NOTCH1 mutations show a better 5-year EFS (P = 0.01); (C) patients with mutated PTEN and not mutated in NOTCH1 compared to the other patients (mutated in PTEN and NOTCH1, mutated in NOTCH1 only or not mutated); patients mutated in PTEN but without NOTCH1 mutations had a tendency to a lower 5-year EFS (P = 0.07). Fig S3. Analyses of Cumulative Incidence of Relapse (CIR) of patients with mutated NOTCH1 compared to patients with not mutated NOTCH1. The two cohorts show a comparable 5-year CIR (P = 0.17). Fig S4. Analyses of Cumulative Incidence of Relapse (CIR) of patient divided based on PTEN and NOTCH1: mutated in PTEN and NOTCH1, mutated in NOTCH1 only, mutated in PTEN and not mutated NOTCH1 or not mutated. Fig S5. Analyses of Cumulative Incidence of Relapse (CIR) of patients with mutated PTEN compared to patients with not mutated PTEN within the MRD non-HR group; patients with a PTEN mutation had an higher 5-year CIR (P = 0.05).
